Sign inCreate account

Report workspace tools

NCT04709458UNKNOWNanonymous

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

Sponsor

Source record

Taiga Biotechnologies, Inc.

Phase

Source record

Phase 1

Modality

AI-normalized

protein therapy

Target

AI-normalized

TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Indication / condition

AI-normalized

Myelofibrosis

Intervention

Source record

TBX-2400

Source & freshness

Source record

NCT ID

NCT04709458

Original source

ClinicalTrials.gov

Source last updated

May 03, 2022

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04709458

Title

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

Sponsor

Taiga Biotechnologies, Inc.

Status

UNKNOWN

Phase

Phase 1

Condition raw

Myelofibrosis, Acute Myelogenous Leukemia

Condition normalized

Myelofibrosis, Acute Myelogenous Leukemia

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Target normalized

TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Interventions

TBX-2400

Public preview

Source record

Taiga Biotechnologies, Inc. is advancing TBX-2400 through a Phase 1 clinical trial aimed at improving outcomes for patients undergoing allogeneic stem cell transplantation for Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF). The potential to shorten the time to immune reconstitution could position TBX-2400 favorably in a market characterized by high unmet needs in hematologic malignancies. The competitive landscape includes established therapies and emerging candidates targeting similar patient populations. Successful trial outcomes could enhance Taiga's market position and attract partnerships or acquisition interest, given the growing focus on innovative therapies in oncology.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04709458

Status

UNKNOWN

Phase

Phase 1

Sponsor

Taiga Biotechnologies, Inc.

Executive brief

Investment-Ready Snapshot

Taiga Biotechnologies, Inc. is advancing TBX-2400 through a Phase 1 clinical trial aimed at improving outcomes for patients undergoing allogeneic stem cell transplantation for Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF). The potential to shorten the time to immune reconstitution could position TBX-2400 favorably in a market characterized by high unmet needs in hematologic malignancies. The competitive landscape includes established therapies and emerging candidates targeting similar patient populations. Successful trial outcomes could enhance Taiga's market position and attract partnerships or acquisition interest, given the growing focus on innovative therapies in oncology.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 03, 2022
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04709458

Indication

Myelofibrosis

Modality

protein therapy

Target

TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Intervention

TBX-2400

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.